- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04036929
Can we Use Estrogen-containing Therapy to Improve Pain in Women After Menopause With Hand Osteoarthritis? (HOPE-e)
Hand Osteoarthritis: Investigating Pain Effects in a Randomised Placebo-controlled Feasibility Study of an Estrogen-containing Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, w6 8rf
- Charing Cross Hospital, Imperial College Healthcare NHS Trust
-
Oxford, United Kingdom, OX3 7HE
- Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust
-
-
Oxfordshire
-
Faringdon, Oxfordshire, United Kingdom, SN7 7YU
- White Horse Medical Practice, Faringdon Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to give informed written consent
- Female, aged 40-65 years old
- In those with an intact uterus: At least 12 months of spontaneous amenorrhea (without any menstrual bleeding in last 12 months) and last menstrual period not more than 10 years ago
- In those who have undergone hysterectomy or are/were using an intrauterine contraceptive device with progesterone local therapy (such as Mirena): Follicle stimulating hormone (FSH) ≥30 milli-International Units per millilitre (mIU/ml) on screening blood test AND a history of menopausal symptoms in the last 1 to 10 years, in keeping with appropriate timing of menopausal status
- Hand pain, aching or stiffness on most days in the last 3 months
- At least 2, painful hand joints of any type (interphalangeal joints (IPJ) or base of thumbs)
Fulfils American College of Rheumatology clinical diagnostic criteria for hand OA (3 or more of following):
- Hard tissue enlargement of 2 or more of the following joints: 2nd or 3rd distal interphalangeal joints (DIPJ), 2nd or 3rd proximal interphalangeal joints (PIPJ), first carpometacarpal joints (CMCJ)
- Hard tissue enlargement of 2 or more of the DIPJs
- Less than 3 swollen metacarpophalangeal joints (MCPJ)
- Deformity of at least one of the joints listed in first point
OR, for those with base of thumb osteoarthritis only not fulfilling these criteria, has clinical symptoms and examination findings consistent with base of thumb osteoarthritis.
- Hand pain has not responded adequately to National Institute for Health and Care Excellence core guidance for management of OA, including the use of paracetamol or non-steroidal anti-inflammatory drug (NSAID) gel, except where there is contraindication or intolerance
- Average hand pain is reported as typically more than 4 out of 10 in severity, or average hand pain in the last 7 days of 4/10 or more on a visual analogue scale
- In the Investigator's opinion, is able and willing to comply with all study requirements
Exclusion criteria
- Other cause of hand pain, including inflammatory arthritis, connective tissue disorder, chronic pain or alternative clinical diagnosis such as tenosynovitis or carpal tunnel syndrome
- Pregnancy or breast feeding, or risk of this during study
Use of one or more prohibited treatments within specified timeframe, or not willing to avoid treatment for the duration of the study:
- Oral contraceptive pill, or systemic HRT within the last 6 months (Use of an intrauterine contraceptive device with progesterone local therapy (Mirena) or vaginal topical estrogen use (known low systemic absorption) are not exclusions to participation)
- Anti-estrogen medication within the last 6 months
- Oral, intramuscular or intraarticular steroid within the last 3 months
- Intraarticular hyaluronan to a hand joint within the last 6 months
- Initiation of new oral analgesia within the last 4 weeks
- Initiation of glucosamine, chondroitin, hand exercises or other relevant non- pharmacological therapy within the last 6 weeks
- Hand surgery within the last 6 months, or planned within the next 6 months
- Medications likely to increase hepatic metabolism of study medication, including:
- St. John's Wort
- Anti-convulsants (phenobarbital, phenytoin, carbamazepine, lamotrigine)
- Some anti-infectives (rifampicin, rifabutin, nevirapine, efavirenz, ritonavir and nelfinavir)
Presence of one or more medical contraindications to the use of systemic hormonal replacement therapy:
- In those aged 40-45 years, FSH <30 mIU/ml on screening blood test, i.e. non- confirmatory of menopausal status
- Any history of breast, endometrial, ovarian or skin cancer
- Any other history of other cancer within 5 years (except treated Basal Cell Carcinoma, BCC)
- Relevant breast issue on routine national breast screening in prior 3 years
- Undiagnosed genital bleeding, or untreated endometrial hyperplasia, active uterine fibroids or endometriosis
- Active or past history of venous thromboembolism (VTE) (including deep venous thrombosis, pulmonary embolism and retinal vein thrombosis), or at high risk of VTE (such as known thrombophilic disorders (such as Protein C, S or anti-thrombin deficiency) or presence of a strong family history of VTE). Women with a first degree relative with a history of VTE, or other strong family history of VTE at the Investigators' discretion.
- Active or past history of arterial thrombo-embolic disease (such as myocardial infarction, angina or stroke) or strong family history of stroke)
- Clinically significant immobility
- Migraine or active epilepsy
- Uncontrolled hypertension (or diastolic pressure greater than 90 mmHg or systolic pressure greater than 145 mmHg at screening visit)
- Uncontrolled diabetes mellitus or uncontrolled hypertriglyceridaemia
- Body Mass Index (BMI) greater than 30
- Active malabsorption syndrome or clinically significant small bowel disease
- Acute liver disease, clinically significant abnormal liver function, active gallbladder disease or porphyria
- Clinically significant renal impairment
- Intolerance to lactose, fructose or glucose (including galactose intolerance, lactase deficiency, fructose intolerance, glucose-galactose malabsorption or sucrase- isomaltase insufficiency)
- Known sensitivity to either conjugated equine estrogens, bazedoxifene or the combination
- Any other significant or uncontrolled disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
- Participants who have participated in another research trial involving an investigational product in the past 8 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Estrogen-bazedoxifene
Tablet, once daily for 6 months.
|
Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
Other Names:
|
Placebo Comparator: Placebo
Closely matched tablet, once daily for 6 months.
|
Placebo oral tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility: Rates of eligible participant identification, rates of recruitment/randomisation from different sources, retention rates
Time Frame: From the date of recruitment opening until the date of recruitment closing, 1 year
|
From the date of recruitment opening until the date of recruitment closing, 1 year
|
|
Feasibility: Frequency of adverse events related to the active study medication
Time Frame: Through study completion, 7 months
|
Through study completion, 7 months
|
|
Feasibility: Bang's Blinding Index (likelihood of unblinding)
Time Frame: Week 24
|
Self-complete questionnaire which assesses likelihood that participant or Investigator have become unblinded
|
Week 24
|
Feasibility: Monitoring study medication compliance (via diaries)
Time Frame: From randomisation to end of treatment at Week 24
|
Participants will be asked to record any missed doses of study medication on a paper diary which will be provided at each visit.
We will ask participants to bring the diary to each study visit and any missed doses will be recorded in the Case Report Form.
|
From randomisation to end of treatment at Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain and function: Average hand pain over last 14 days (NRS 0-10)
Time Frame: Collected at: Baseline, Week 4, Week 12, Week 24
|
Numerical Rating Scale 0-to-10, where 0 is "no pain" and 10 is "pain as bad as you can imagine"
|
Collected at: Baseline, Week 4, Week 12, Week 24
|
Pain and function: Remote pain-rating prior to a visit (NRS 0-10)
Time Frame: Collected at: Baseline, Week 4, Week 12, Week 24
|
Numerical Rating Scale 0-to-10, where 0 is "no pain" and 10 is "pain as bad as you can imagine"
|
Collected at: Baseline, Week 4, Week 12, Week 24
|
Pain and function: Prevalence of joint pain elsewhere (pain manikin)
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Prevalence of joint pain elsewhere in the 4 weeks preceding the study visit
|
Collected at: Baseline, Week 12, Week 24
|
Pain and function: Functional Index for Hand OA (FIHOA)
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Validated measurement of hand OA-related functional impairment.
It includes 10 questions scored according to a 4-grade scale.
The score ranges from 0 (no functional impairment) to 30 points (maximal impairment).
|
Collected at: Baseline, Week 12, Week 24
|
Pain and function: EQ-5D-5L
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Validated measurement of quality of life across five dimensions and their associated levels of severity on a 1 (no problems) to 5 (extreme problems) scale.
|
Collected at: Baseline, Week 12, Week 24
|
Menopause symptoms: The Menopause Specific Quality of Life Questionnaire (MENQOL)
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Validated measurement of menopausal symptoms and their associated degree of severity; 30 items in a Likert-scale format. Items are rated as present or not present and if present how bothersome, on a 0 (not bothersome) to 6 (extremely bothersome) scale. The interventional version is being used here, which includes an additional 3 questions relevant to Hormonal Replacement Therapy (HRT) use which has been used in a trials setting. |
Collected at: Baseline, Week 12, Week 24
|
Menopause symptoms: Greene Climacteric Scale
Time Frame: Collected at: Baseline, Week 12, Week 24
|
A 21-item validated questionnaire that measures a variety of menopausal symptoms on a 4-point Likert scale (0 = "not at all" to 3 = "extremely"), plus one sexual function probe.
|
Collected at: Baseline, Week 12, Week 24
|
Joint appearance: Cosmesis score of Michigan Hand Questionnaire (4 questions, questions 28-31)
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Subdomain of hand-specific outcomes instrument that measures outcomes of patients with conditions of, or injury to, the hand or wrist.
|
Collected at: Baseline, Week 12, Week 24
|
Joint appearance: Investigator-recorded tender and swollen joint counts
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Investigator examination of tender and swollen hand joints, binary recording (1 swollen, 0 not swollen).
|
Collected at: Baseline, Week 12, Week 24
|
Joint appearance: Photographic recording of swollen hand joints
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Standardised digital photography of hands
|
Collected at: Baseline, Week 12, Week 24
|
Joint function: Jamar grip strength - average of 3 measurements
Time Frame: Collected at: Baseline, Week 12, Week 24
|
Handgrip strength will be measured in kilograms to the nearest hundred grams in both hands using a Jamar dynamometer. Both hands will be alternately assessed three times and the average score recorded. |
Collected at: Baseline, Week 12, Week 24
|
End of Treatment questionnaire (study-specific)
Time Frame: Week 24
|
A study specific end of treatment questionnaire will be designed to include items on acceptability.
|
Week 24
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Bone Density Conservation Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Bazedoxifene
- Estrogens
Other Study ID Numbers
- HOPE-e
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hand Osteoarthritis
-
University of ZurichWithdrawnHand Osteoarthritis | Wrist Injuries | Wrist Fracture | Hand Injury Wrist | Wrist Arthritis | Hand Fracture | Hand Sprain
-
FoU Center SpenshultThe Swedish Rheumatism AssActive, not recruitingOsteoarthritis, Knee | Osteoarthritis Hand | Osteoarthritis GeneralizedSweden
-
Henning BliddalCompletedOsteoarthritis Hand | Osteoarthritis FingerDenmark
-
Diakonhjemmet HospitalNot yet recruitingHand Osteoarthritis | Erosive OsteoarthritisNorway
-
Diakonhjemmet HospitalOslo University HospitalRecruitingHand Osteoarthritis | Erosive OsteoarthritisNorway
-
Vita CareTegos S.A.CompletedOsteoarthritis | Osteoarthritis Hand | Osteoarthritis Finger | Osteoarthritis Both HandsBrazil
-
Cedars-Sinai Medical CenterMusculoskeletal Transplant FoundationRecruitingOsteoarthritis HandUnited States
-
BioibericaUnknown
-
Diakonhjemmet HospitalNorwegian Fund for Postgraduate Training in PhysiotherapyCompleted
-
Charite University, Berlin, GermanyRecruitingHand OsteoarthritisGermany
Clinical Trials on Placebo oral tablet
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
University of OxfordNovo Nordisk A/SRecruitingDiabetes Mellitus, Type 2United Kingdom
-
Fulcrum TherapeuticsTerminated
-
EicOsis Human Health Inc.CompletedHealthy AdultsUnited States
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
The Mind Research NetworkTerminatedSmoking Cessation | Tobacco Use DisorderUnited States
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis CChina